Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251963 · ClinicalTrials.gov registry record · Phase 2
Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT03251963 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 131 participants.
The verdict
NCT03251963, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
The aim of this research is to better understand how patient-level factors can be used to predict the appropriate enoxaparin dose to maximize venous thromboembolism (VTE) risk reduction and minimize bleeding.
Interventions
- DRUG Fixed Dose Enoxaparin
- DRUG Variable Dose Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2017-09-15 |
| Est. Completion | 2019-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03251963
The ClinicalTrials.gov registry entry for NCT03251963 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fixed Dose Enoxaparin is the first listed.
NCT03251963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03251963 about?
NCT03251963 is a clinical study titled "Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients". The aim of this research is to better understand how patient-level factors can be used to predict the appropriate enoxaparin dose to maximize venous thromboembolism (VTE) risk reduction and minimize bleeding.
What is the current status of trial NCT03251963?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2017-09-15. Estimated completion is 2019-07-27.
What interventions are being tested in trial NCT03251963?
The interventions under investigation include: Fixed Dose Enoxaparin (DRUG), Variable Dose Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT03251963?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.